Rep. Marjorie Taylor Greene Buys Eli Lilly and Company (NYSE:LLY) Shares

Posted by Lindsey Winhoffer on Jan 29th, 2025

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on January 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in Eli Lilly and Company stock on January 21st.

Representative Marjorie Taylor Greene also recently made the following trade(s):

Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 1/21/2025.
Purchased $1,001 – $15,000 in shares of NextEra Energy (NYSE:NEE) on 1/21/2025.
Purchased $1,001 – $15,000 in shares of Old Dominion Freight Line (NASDAQ:ODFL) on 1/21/2025.
Purchased $1,001 – $15,000 in shares of Palo Alto Networks (NASDAQ:PANW) on 1/21/2025.
Purchased $1,001 – $15,000 in shares of Devon Energy (NYSE:DVN) on 1/21/2025.
Purchased $1,001 – $15,000 in shares of Advanced Micro Devices (NASDAQ:AMD) on 1/21/2025.
Purchased $1,001 – $15,000 in shares of Kinder Morgan (NYSE:KMI) on 1/21/2025.
Purchased $1,001 – $15,000 in shares of Norfolk Southern (NYSE:NSC) on 1/21/2025.
Purchased $1,001 – $15,000 in shares of Cardinal Health (NYSE:CAH) on 1/21/2025.
Purchased $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 1/21/2025.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $804.87 on Wednesday. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The stock’s 50 day moving average price is $778.30 and its two-hundred day moving average price is $847.30. The firm has a market capitalization of $764.08 billion, a price-to-earnings ratio of 87.01, a P/E/G ratio of 1.59 and a beta of 0.41. Eli Lilly and Company has a 12-month low of $637.00 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The firm had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. Eli Lilly and Company’s revenue for the quarter was up 20.4% on a year-over-year basis. During the same quarter last year, the business posted $0.10 EPS. On average, analysts anticipate that Eli Lilly and Company will post 12.98 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, February 14th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a yield of 0.75%. Eli Lilly and Company’s dividend payout ratio is 56.22%.

Eli Lilly and Company announced that its board has initiated a stock repurchase plan on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to reacquire up to 2% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on LLY. Wells Fargo & Company lowered their price objective on Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating on the stock in a research note on Tuesday. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, January 22nd. Citigroup lowered their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research report on Tuesday. Bank of America reaffirmed a “buy” rating and issued a $997.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Finally, Sanford C. Bernstein assumed coverage on Eli Lilly and Company in a research report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 target price for the company. Four analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $997.22.

Get Our Latest Stock Report on LLY

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Canvas Wealth Advisors LLC increased its stake in Eli Lilly and Company by 6.8% in the fourth quarter. Canvas Wealth Advisors LLC now owns 1,512 shares of the company’s stock valued at $1,167,000 after acquiring an additional 96 shares during the last quarter. Liberty Capital Management Inc. increased its stake in Eli Lilly and Company by 4.7% in the fourth quarter. Liberty Capital Management Inc. now owns 2,250 shares of the company’s stock valued at $1,737,000 after acquiring an additional 100 shares during the last quarter. LJI Wealth Management LLC increased its stake in Eli Lilly and Company by 1.8% in the fourth quarter. LJI Wealth Management LLC now owns 7,131 shares of the company’s stock valued at $5,505,000 after acquiring an additional 127 shares during the last quarter. HTLF Bank increased its stake in Eli Lilly and Company by 7.3% in the fourth quarter. HTLF Bank now owns 828 shares of the company’s stock valued at $639,000 after acquiring an additional 56 shares during the last quarter. Finally, Tevis Investment Management increased its stake in Eli Lilly and Company by 62.8% in the fourth quarter. Tevis Investment Management now owns 1,506 shares of the company’s stock valued at $1,163,000 after acquiring an additional 581 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia’s 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2025. Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia’s 14th Congressional District. She declared candidacy for the 2024 election. Marjorie Taylor Greene earned a bachelor’s degree in business administration from the University of Georgia. Greene’s career experience includes co-owning construction company Taylor Commercial and founding and owning a CrossFit gym.

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.